The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis

Learn more about:
Related Clinical Trial
Research on Optimization and Evaluation of Oral Cancer Screening Methods Low-Cost, Portable Flexible Nasopharyngoscope in Head & Neck Cancers in Low Resource Settings Topical Aldara (Imiquimod) for Oral Cancer Diagnostic Accuracy of Salivary Gamma-synuclein in Oral Malignant and Premalignant Lesions LLL Phototherapy in Oral Lesions Resulting From Anti-neoplastic Treatment Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survival Trial Understanding Non-radiotherapy-based Development of Trismus Use of Ultrasound for Measuring Size of Oral Tongue Cancers Green Tea Mouthwash on the Oral Health Status in Oral Cancer Patients Oral Cancer Screening and Education in Hong Kong Evaluating Oral Visual Inspection in the Control of Oral Cancer Inductive Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients Effects of EMG Visual Feedback for Spinal Accessory Nerve Dysfunction After Neck Dissection: a Randomized Clinical Trial Prevention of Oral DNA Damage by Black Raspberries Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma NBI in Oral Cavity Cancer Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer Physical Activities by Technology Help (PATH) Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients Patient Evaluation for Head and Neck Surgery Branch Studies Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Quality of Life in Patients Treated for Tongue and/or Jaw Neoplasia Before and After Speech Therapy Prospective Analysis of Robot-Assisted Surgery Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery Extended Follow-Up of Young Women in Costa Rica Who Received Vaccination Against Human Papillomavirus Types 16 and 18 and Unvaccinated Controls Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Cigarette Smoking and Oral Microbiota Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. MSOT Using Cetuximab-800CW for Detection of Cervical Lymph Node Metastases Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis Least Invasive Nonlinear Light Microscopy Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN Trismus Trial of Therabite vs Wooden Spatula in Head and Neck Cancer Patients Improving Access to Control of Diseases for Women IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC Submandibular Gland Preservation in Neck Dissection uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC Autofluorescence Detection of Oral Malignancies and Database and Biospecimen Collection to Identify Biomarkers of Head and Neck Tumor Progression The Use of Functional Confections in Promoting Oral Health The Oral Microbiome and Upper Aerodigestive Squamous Cell Cancer A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma Evaluation of the Photobiomodulation Using LED Lamp for Curative Treatment of Radio-induced Mucositis. Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions Wild Type p53 Adenovirus for Oral Premalignancies Acupuncture Effect on Digestion in Critically Ill Post-Operative Oral and Hypo-pharyngeal Cancer Patients Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions Trial of IIb Preserving Neck Dissection Expression of Hypoxia-Inducible Factor-α in Oral Precancers and Cancers Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography Innovative Approach to Triage Oral Precancer The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma Rehabilitation Outcomes in Head and Neck Survivors Evaluation of a Multispectral Vision Enhancement System for Assessment of Oral Mucosal Lesions The Relation of Microtubule-Associated Protein 2 and Cell Migration Sensitivity and Specificity of Serum and Salivary CYFRA21-1 in the Detection of Malignant Transformation in Oral Potentially Malignant Mucosal Lesions (Diagnostic Accuracy Study) Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue Oral Pathology Asynchronous Telementoring Pilot Study Polarized Reflectance Spectroscopy for Oral Lesions A Study of the Effects of PEITC on Oral Cells With Mutant p53 Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions Analysis of the Variation in Caspase-8 Availability and Cleavage in Oral Squamous Cell Carcinoma The Role of microRNA-29b in the Oral Squamous Cell Carcinoma Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer – COOLS TRIAL Assessment of Mandibular Bone Invasion With MRI Using SWIFT Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral Cancer Patients Epstein-Barr Detection in Oral Cancer Workplace Tobacco Cessation And Oral Cancer Screening Study Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer. Elective vs Therapeutic Neck Dissection in Treatment of Early Node Negative Squamous Carcinoma of Oral Cavity Personalized Survivor Care Plan for Oral Cancer Patients-Effects on Physical-Psychological Functions and Return-to-Work Dental Hygienists and Dentists as Providers of Oral Mucosa Screening and Brush Biopsies Effects of Mouth-opening Training on the Maximum Interincisal Opening Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer Oral State of Patients Affected by an Oral Cancer Before and After Radiotherapy – 3-years Prospective Study Erlotinib Prevention of Oral Cancer (EPOC) Oral Cancer Screening in Mumbai, India by Primary Health Care Workers Study on the Carcinogenesis of Gα12 in Oral Cancer, and the Treatment of Oral Cancer Using Ga12 Inhibitor. The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor Study on the Carcinogenesis of SOX-9 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer. Validation of DNA Methylation Biomarkers for Oral Cancer Detection Validation of DNA Methylation Biomarkers for Oral Cancer Detection-Follow up Study Rehabilitation Outcomes of Shoulder Function in Oral Cancer Survivors Cancer Survivors Behavior Change on Oral Cancer Patients After a Localized Behavior Change Model Intervention Expression of VEGF-C and VEGF-CR in Oral Cancers and Premalignant Lesions PET/CT and Sentinel Node in Oral Cancer Validation of DNA Methylation Biomarkers for Oral Cancer Detection Web-based Education on Oral Cancer for Primary Care Physicians in Ohio Analysis Of Sensory Recovery Of Donor Size And Quality Life In Oral Cancer Patients Using an APP in Post Oral Cancer Surgery to Affect Patients’ Needs and Quality of Life.

Brief Title

The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis


Brief Summary

      The purpose of this study is to investigate the role of lymphangiogenesis in the metastasis
      of head and neck cancer.
    

Detailed Description

      Head and neck cancer is a major, worldwide cause of morbidity and mortality. As long as the
      neoplasm is confined to its organ of origin, the patient can be cured through surgical
      removal of the tumor mass. Unfortunately, many cancers metastasize to other sites in the
      body, and metastasis is the leading cause of death in cancer patients. In principle, cancer
      cells can spread within the body by different mechanisms, such as direct invasion of
      surrounding tissues (per continuitatem), spread via the blood vascular system (hematogenous
      metastasis) and spread via the lymphatic system (lymphatic metastasis). Tumor cells can
      invade either the blood or lymphatic vessels to access the general circulation and then
      establish themselves in other tissues. Clinicopathological data suggest that the lymphatics
      are an initial route for the spread of solid tumors. Infiltration of lymphatic vessels by
      tumor cells has been found at the periphery of many experimental and human tumors, and the
      lymphatic system has been recognized as a conduit for tumor cell dissemination. Though the
      significance of angiogenesis for tumor progression has been well documented, the molecular
      mechanisms regulating the growth and function of lymphatic vessels are largely unknown.

      Vascular endothelial growth factors, first identified in 1989, are well-known angiogenic
      agents and targets for anti-cancer therapies. Now it appears that VEGF-C, one recently-cloned
      member of the vascular endothelial growth factor (VEGF) family, is also involved in
      developmental and tumor-induced lymphangiogenesis. VEGF signals through two tyrosine kinase
      receptors, VEGFR-1 and VEGFR-2, which are expressed predominantly but not exclusively on
      vascular endothelial cells. As neither VEGFR-1 nor VEGFR-2 appears to be highly expressed in
      lymphatic endothelium, it was not surprising that a third VEGF receptor, VEGFR-3, was found
      to be predominantly expressed on lymphatic vessels during development. What was surprising,
      however, was that VEGF was not found to bind to VEGFR-3. Instead, VEGF-C was discovered to be
      ligand for VEGFR-3. Research groups provide direct evidence that VEGF-C is not only an
      important regulator of lymph vessel growth (lymphangiogenesis) in vivo but it also enhances
      lymphatic metastasis. Using experimental approaches, Mäkinen et al., Skobe et al., as well as
      Mandriota et al. demonstrate an important role of VEGFR-3 and its ligand, VEGF-C, in
      developmental and tumor-induced lymphangiogenesis. In normal adult human tissues, the VEGF-C
      receptor VEGFR-3 (FLT-4) is predominantly expressed by lymphatic endothelia. Expression of
      VEGF-C occurs in a variety of human tumors such as breast, colon, lung, thyroid, gastric,
      squamous cell cancers, mesotheliomas, neuroblastomas, sarcomas and melanomas. Moreover,
      expression of VEGF-C mRNA has recently been shown to correlate with the rate of metastasis to
      lymph nodes in breast, colorectal, gastric, thyroid, lung and prostate cancers. To date,
      however, lymphangiogenesis has not been causally linked to tumor metastasis.

      Cyclooxygenase-2 (COX-2) enzyme catalyzes the synthesis of prostaglandins. COX-2 is an
      immediate-early response gene induced by inflammation, growth factors, tumor promoters,
      oncogenes, and carcinogens. Increased levels of COX-2 may contribute to carcinogenesis by
      modulating xenobiotic metabolism, apoptosis, immune surveillance, and angiogenesis. Any
      significant increase in tumor mass must be preceded by an increase in vascular supply to
      deliver nutrients and oxygen to the tumor. Recently, levels of COX-2 were found to correlate
      with both VEGF expression and tumor vascularization in HNSCC. This finding in human tissues
      is consistent with prior evidence that overexpression of COX-2 in epithelial cells led to
      enhanced production of VEGF and the formation of capillary-like networks. Although COX-2
      contributes to the regulation of angiogenesis, its role in lymphangiogenesis is not clear.

      IL-6 is a secreted, multifunctional glycoprotein. Through binding to α-chain (IL-6-R, gp80)
      and subsequently recruiting the β-chain (gp130) of the receptor, IL-6 performs various
      biological functions. The diversity of IL-6 signaling mediated via gp130 explains its
      functional pleiotropy. IL-6 regulates inflammatory reactions, immune responses, hepatic
      acute-phase protein synthesis, and several other important physiological processes.
      Interestingly, the influence of IL-6 in human cancers is varied depending on the cell types.
      For example, IL-6 has been demonstrated to promote growth of multiple myeloma, Kaposi's
      sarcoma, and prostatic cancer cells, while inhibiting the proliferation of lung and breast
      cancer cells. Previous investigations have confirmed that IL-6 is important in both
      physiological and pathological angiogenesis. Additionally, recent study supports the
      hypothesis that IL-6 facilitates tumorigenesis of cervical cancer via VEGF-mediated
      angiogenesis. Nevertheless, whether IL-6 could regulate the expression of VEGF-C and what is
      its role in lymphangiogenesis still need to be clarified.

      Inhibition of angiogenesis is currently considered one of the most promising therapeutic
      strategies to inhibit cancer growth because it presumably can act on any tumor type, does not
      induce resistance of tumor cells (and can therefore be used in repeated therapeutic cycles)
      and has little effect on normal tissues. It now needs to be determined whether the same holds
      true for tumor lymphangiogenesis.

      Metastases of head and neck cancers occur frequently through the lymphatic system, and the
      extent of lymph node involvement is a key prognostic factor for the diseases. In this study,
      we will conduct a systematic analysis of VEGF-C, COX-2 and IL-6 expressions and will try to
      find the correlation between their expressions, lymphatic metastases and patient survival.
      Next, we will investigate the relationship between VEGF-C, COX-2 and IL-6, and further
      clarify their effects on tumor growth. Undoubtedly, the findings of this study will help us
      understand whether lymphangiogenesis could be a focal point of anti-cancer research. If HNSCC
      tumors that express high levels of VEGF-C show a consistently higher incidence of lymphatic
      metastasis, then inhibition of VEGFR-3 function may be a novel approach to inhibit lymphatic
      metastasis in patients.
    


Study Type

Observational




Condition

Oral Cancer



Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

100

Start Date

August 2004



Eligibility Criteria

        Inclusion Criteria:

          -  Head and neck squamous cell carcinoma

        Exclusion Criteria:

          -  Other pathological type
      

Gender

All

Ages

30 Years - 75 Years

Accepts Healthy Volunteers

No

Contacts

Ching-Ting Tan, MD, PhD, 886-2-23123456, [email protected]

Location Countries

Taiwan

Location Countries

Taiwan

Administrative Informations


NCT ID

NCT00173381

Organization ID

9461700657



Study Sponsor

National Taiwan University Hospital


Study Sponsor

Ching-Ting Tan, MD, PhD, Principal Investigator, National Taiwan University Hospital


Verification Date

June 2005